<DOC>
	<DOC>NCT00412997</DOC>
	<brief_summary>The phase I study will evaluate the safety, efficacy and pharmacokinetics of LBH589B in adult patients with advanced solid tumors or Cutaneous T-cell lymphoma</brief_summary>
	<brief_title>LBH589 in Adult Patients With Advanced Solid Tumors or Cutaneous T-cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, T-Cell</mesh_term>
	<mesh_term>Lymphoma, T-Cell, Cutaneous</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<criteria>Patients with either a) histologicallyconfirmed, advanced solid tumors whose disease has progressed despite standard therapy or for whom no standard therapy exists, or b) cytopathologically confirmed cutaneous Tcell lymphoma (CTCL) whose disease has progressed despite standard therapy or for whom no standard therapy exists. Inclusion is irrespective of stage of disease or extent of prior therapy. World Health Organization (WHO) Performance Status of ≤ 2 Patients must have the adequate laboratory values Patients with a history of primary CNS tumors Patients with any history of brain metastases Patients with any peripheral neuropathy ≥ CTCAE grade 2 Patients with unresolved diarrhea ≥ CTCAE grade 2 Impairment of cardiac function Impairment of gastrointestinal (GI) function or GI disease Liver or renal disease Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>advanced solid tumor</keyword>
	<keyword>Cutaneous T-cell lymphoma</keyword>
	<keyword>Phase I</keyword>
	<keyword>HDAC inhibitor</keyword>
	<keyword>Adult patients</keyword>
</DOC>